Pfizer booster dose offers exceptionally high levels of protection against Covid and all variants, study shows

·2 min read

Watch: Pfizer/BioNTech says booster dose is 95.6% effective in phase 3 trial

A booster dose of the Pfizer-BioNTech vaccine offers exceptionally high levels of protection against coronavirus, including the Delta variant, new trial data shows.

Pfizer said its trial of 10,000 people found that the risk of symptomatic infection was reduced by 95.6 per cent in people who received a third dose, compared to those who were vaccinated with two.

“Based on these findings we believe that, in addition to broad global access to vaccines for everyone, booster vaccinations could play an important role in sustaining pandemic containment and a return to normality,” said Ugur Sahin, head of BioNTech.

Participants in the study were given a booster jab or a placebo 11 months on average after receiving their second dose.

Pfizer said only five cases of Covid-19 were reported among the booster cohort, compared to 109 in the placebo group.

The median age of the participants was 53 years, with 55.5 per cent of participants being between 16 and 55 years and 23.3 per cent being 65 years or older.

The trial took place during a period when the Delta variant was prevalent, proving that the booster jab is effective against this form of the virus.


Pfizer and BioNTech said the effectiveness of the vaccine was “consistent” across age, sex, race, ethnicity, and those with underlying health conditions. They also said that the administration of a third dose was safe.

The two companies said they would submit detailed results of the trial to the Food and Drug Administration in the US, the European Medicines Agency, and other regulatory agencies as soon as possible.

US, EU and UK regulators have already authorised a third dose of Covid-19 vaccines by Pfizer-BioNTech and Moderna for patients with compromised immune systems, who are likely to have weaker protection from the two-dose regimens.

Research has shown that the effectiveness of the Pfizer vaccine against symptomatic disease falls from 96 per cent to 84 per cent four months after a second dose. 

Amid fears of waning immunity – though the vaccine, along with other authorised jabs, continues to offer high levels of protection against hospitalisation and death – a number of countries have already pushed ahead with national booster programmes for elderly and vulnerable groups.

The move has proved controversial and divisive, with billions of people across the world yet to receive a first vaccine dose.

In the UK, the government has urged the public to come forward for a booster jab when invited to do so. 

With cases back on the rise in Britain and the NHS facing ever-mounting pressure, health secretary Sajid Javid warned people that unless they “do their bit” by taking up the offer of vaccines and booster jabs, they could lose the freedoms they have enjoyed since the lifting of all restrictions in July.

Watch: Mass. preparing plans to get COVID-19 vaccines to kids

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting